The Hon. John Brumby MP has opened a new research facility funded by the Australian Cancer Research Foundation that will assist with the early detection of colon cancer, the most common internal cancer.
The new Ludwig Institute for Cancer Research (LICR) facility, situated at the Royal Melbourne Hospital, features a mass spectrometer that offers improved capability for the early detection, diagnosis and treatment of colon cancer.
The recently purchased mass spectrometer is the centre piece of the Australian Cancer Research Foundation (ACRF) Cancer Proteomics Program at the LICR, which was made possible with a $1 million grant from ACRF.
Colon cancer is among the three most common cancers in the Western world, affecting almost 1 in 20 Australians and leading to about 5,000 deaths per year.
According to ACRF, the LICR facility further cements Melbourne scientists as international leaders in cancer research and follows another ACRF-funded facility also launched by Minister Brumby last week.
Minister Brumby opened the Drug Discovery Facility at St Vincent’s Institute of Medical Research, bringing ACRF’s total funding to Melbourne cancer research institutes to $9.9 million (of a total of $18.5 million throughout Australia) in the past two years.
ACRF Chairman Tom Dery presented a $1,000,000 cheque to Professor Tony Burgess, Director of LICR Melbourne and Mr Ed McDermott, LICR Global President.
“The cost of treating cancer in Australia is more than $2 billion and the work at Ludwig to find a breakthrough for one of the most serious cancers affecting Australians – colon cancer – is the sort of project ACRF is committed to funding,” said Mr Dery.
“We are optimistic there will be breakthroughs for colon cancer diagnosis and treatment and the Ludwig Institute for Cancer Research is certainly at the forefront of colon cancer research, not just in Australia, but globally.”
LICR’s Global President, Mr McDermott added: “There are a variety of agencies funding research, but the ACRF is fulfilling a critical role in Australia by granting large, intercessional grants for infrastructure, not available elsewhere”.
Professor Burgess said scientists had identified the mistakes which cause colon cancer.
“It is now time to detect these cancerous proteins and learn how to target the cancer with smart drugs. The ACRF Cancer Proteomics Program will provide a modern approach to killing cancer cells,” he said.
Dr. Peter Gibbs, an Associate Investigator at LICR, described the acquisition of the new mass spectrometer as “a major step forward in our bowel cancer research”.
“This technology will significantly advance development of treatment strategies tailored specifically for an individual patient,” he added.
The mass spectrometer is a highly selective technique of identifying specific proteins for the possible early detection of malignant cells as yet undetected in the body. The new machine improves data sensitivity at least a hundred fold.
Caroline Cody, LICR – mobile 0430134743 or David Brettell, ACRF – 02 9223 7833
Go to LICR facility on this site or visit Ludwig at http://www.ludwig.edu.au/branch